BioAffinity Technologies today announced it appointed Michael Dougherty as chief financial officer, effective immediately.
Dougherty will report directly to President and CEO Maria Zannes. He has more than 20 years of experience in financial management and business strategy. Former CFO Michael Edwards will remain as a consultant to ensure a smooth transition.
“We are delighted to welcome Mike to our executive leadership team. He brings a tremendous skill set developed in senior positions at Amazon and Russell Investments. His expertise in financial management will play an important role in the nationwide commercial rollout of CyPath Lung,” Zannes said in a news release. “His experience in strategy development and M&A will be crucial as we expand the CyPath brand into other indications and pursue therapeutics opportunities. I look forward to his input and leadership as we increase visibility for our Company among investors, analysts and the broader financial community.”
Most recently, Dougherty was CFO of Alexa Business Domains, Amazon’s Alexa AI and Voice division, where he was responsible for financial strategy over Alexa’s multi-billion dollar investments. Prior to that, Dougherty was chief financial and operating officer of Tint and CGO at FileStack. He has held various financial positions at Amazon Pay, Russell Investments and Medisystems Corporation.
“As a finance executive at both large enterprise business units and private equity-backed growth firms, my focus has always been on operational excellence, legal and regulatory compliance, and stewardship of company resources. I am excited to join bioAffinity Technologies during this pivotal time in the evolution of its business,” Dougherty said. “CyPath Lung has significant potential to improve early-stage lung cancer diagnosis and extend lives. I look forward to leading the financial strategy to support its expansion and create value for our shareholders.”